Standard: this guide onlyAll-Access Lifetime: all 45 guides + downloadsEducational content only
Cagrilintide Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Cagrilintide at a glance
What it is
Cagrilintide (AM833), a long-acting synthetic amylin analog / amylin-receptor agonist
Researched for
Weight management and metabolic disease in obesity/overweight and type 2 diabetes research contexts
Commonly reported range
0.25 mg to 4.5 mg once weekly in trials; 2.4 mg is the most-studied maintenance example
Route reported
Subcutaneous injection
Reported frequency
Once weekly
Reported cycle
Trials used ~4-week step-up titration (e.g. 0.25 mg escalating toward 2.4 mg by ~week 17)
Plasma half-life
Approximately 7-8 days (reported ~159-195 hours)
Regulatory status
Investigational; not FDA-approved as a standalone. CagriSema (cagrilintide + semaglutide) under FDA review in 2026
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
Cagrilintide is a long-acting synthetic analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. In published research it acts as a non-selective amylin-receptor agonist, binding the calcitonin receptor (CTR) complexed with receptor-activity-modifying proteins (RAMP1 and RAMP3) in appetite-regulating regions of the brain. Activation of these receptors is reported to slow gastric emptying and enhance satiety signaling, reducing food intake. Because this pathway is distinct from GLP-1 signaling, cagrilintide is studied in combination with GLP-1 receptor agonists such as semaglutide, where the two mechanisms are reported to produce additive appetite suppression. Structural acylation gives the molecule its long duration of action, supporting once-weekly administration in trials.
Researched effects
In clinical research, cagrilintide has been associated with reduced appetite, increased satiety, and dose-dependent body-weight reduction; Phase 2 data reported roughly 10-11% weight loss versus placebo at ~26 weeks as a monotherapy example, and Phase 3 CagriSema data reported substantially larger reductions when combined with semaglutide. These are reported research findings, not guaranteed outcomes, and individual results in studies varied. Nothing here should be read as a promise of efficacy or a personal recommendation.
Evidence & regulatory status
Evidence base: Phase 1 and Phase 2 trials characterized pharmacokinetics and dose-dependent weight loss; Phase 3 programs (e.g. REDEFINE) evaluated the CagriSema combination with semaglutide.
Regulatory status: Cagrilintide is investigational and not independently FDA-approved. CagriSema (cagrilintide + semaglutide) was submitted to the FDA in late 2025 with a decision expected in 2026; it is not an approved product at time of writing.
Research-use framing: Material sold as cagrilintide is for laboratory and research purposes only and is not a medicine; described dosing reflects reported trial and community protocols, not clinical guidance.
Dosage — reported ranges (overview)
The figures below are examples of what has been reported in clinical trials and research/community settings, not a recommendation. Trials commonly began at a low once-weekly dose (around 0.25 mg) and escalated in roughly 4-week steps, with 2.4 mg once weekly being the most-studied maintenance example and doses up to 4.5 mg examined in dose-finding work. Because cagrilintide has a long half-life, once-weekly dosing was the standard schedule in studies.
The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.
Reconstitution — bac-water math
Cagrilintide is dosed in milligrams, so reconstitution is a concentration calculation. Add bacteriostatic water to the lyophilized vial and the concentration is simply the vial's total mg divided by the water volume in mL. On a U-100 insulin syringe, 100 units equals 1 mL, so the number of units to draw for a given dose is: dose (mg) / concentration (mg/mL) x 100. Worked example: a 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL. A 2.4 mg example dose is then 2.4 / 5 = 0.48 mL, which is 48 units on a U-100 syringe. This is concentration math only, not a personal dose. Add water slowly down the vial wall and swirl gently rather than shaking.
Bac water added
Concentration
0.5 mg (low example)
2.4 mg (high example)
1 mL
10 mg/mL
0.5 mg = 5 units
2.4 mg = 24 units
2 mL
5 mg/mL
0.5 mg = 10 units
2.4 mg = 48 units
3 mL
3.33 mg/mL
0.5 mg = 15 units
2.4 mg = 72 units
This is concentration math, not a dose recommendation.
Pre-fills example values. Every field remains editable.
The amount printed on the vial or listed on a product page.
mL
Liquid volume used for the concentration calculation.
The mass amount to convert into liquid volume for this math example.
4. Insulin syringe size
Your result
Syringe-unit reading
10 units
= 0.1 mL · 250 mcg target amount
Concentration
2.5mg/mL
Per insulin unit
25mcg
Portions per vial
20
Volume
0.1mL
This calculator is an educational tool for laboratory and research math only. The peptides referenced are research compounds not intended for human or veterinary use, and example values are not medical advice or personal-use instructions. Follow applicable research protocols and regulations.
How the calculator works
Concentration
peptide ÷ liquid
Total peptide divided by liquid volume gives the concentration per mL.
Volume
target ÷ concentration
The target mass divided by concentration gives the liquid volume.
Syringe units
volume × 100
For insulin units, 100 units equals 1 mL, so mL is multiplied by 100.
Worked example: A 5 mg vial plus 2 mL liquid creates a 2.5 mg/mL concentration. A 250 mcg target amount equals 0.1 mL, or 10 insulin units. The vial contains 20 such portions.
Frequently asked questions
How much bacteriostatic water should I enter?+
There is no single calculator-default amount. The liquid volume controls concentration: more liquid creates a less concentrated solution and a larger volume reading for the same target amount; less liquid creates a more concentrated solution and a smaller volume reading.
How do insulin syringe units relate to mL?+
For this math tool, 100 insulin units equals 1 mL, and 1 unit equals 0.01 mL. The 0.3 mL, 0.5 mL, and 1.0 mL options change capacity, not the unit-to-mL relationship.
What is the difference between mg, mcg, and units?+
Milligrams and micrograms measure peptide mass: 1 mg = 1,000 mcg. Syringe units measure liquid volume. Reconstitution math connects mass and volume by using concentration.
Does changing the liquid volume change the total peptide in the vial?+
No. The total peptide amount entered for the vial remains fixed. Changing the liquid volume only changes concentration and the resulting volume shown by the calculator.
Injection / administration basics
In research protocols cagrilintide is described as a subcutaneous injection using a small-gauge insulin syringe, rotating sites (commonly abdomen or thigh) once weekly. Reconstituted solution is drawn to the calculated unit mark; foaming and vigorous agitation are avoided during preparation. This describes reported handling in research settings and is not instruction for personal use.
Half-life & frequency rationale
Cagrilintide has a long plasma half-life reported at roughly 7-8 days (approximately 159-195 hours across studied doses), which is the basis for once-weekly dosing in trials. Steady-state accumulation over several weeks is consistent with this extended half-life.
Side effects, safety & contraindications
In trials the most commonly reported side effects were gastrointestinal, including nausea, vomiting, constipation, and decreased appetite, generally described as dose-related and more frequent during dose escalation. Injection-site reactions were also reported. Human data outside the trial setting remain limited, and standalone long-term safety has not been established since the compound is still investigational. These are reported observations, not an exhaustive safety profile, and nothing here is medical advice.
Stacking — overview
The most prominent reported combination is with the GLP-1 receptor agonist semaglutide, marketed in development as CagriSema, where the amylin and GLP-1 pathways are reported to act additively on appetite. Community and research discussions also describe pairing amylin analogs with other GLP-1 or dual-agonist compounds. These reflect reported pairings, not recommendations.
CagriSema (clinical combination)
Cagrilintide + Semaglutide
Amylin + dual incretin (reported)
Cagrilintide + Tirzepatide
Next-gen incretin pairing (reported)
Cagrilintide + Retatrutide
Storage & handling
Lyophilized (unreconstituted) vials are typically stored refrigerated and protected from light; many sources note short-term room-temperature stability of the sealed powder before use.
After reconstitution, keep refrigerated (about 2-8 C), protect from light, and use within a few weeks; do not freeze the reconstituted solution and avoid shaking.
References
This guide summarizes peer-reviewed pharmacology and clinical-trial literature on cagrilintide (including Journal of Medicinal Chemistry development work and Phase 2/3 obesity and type 2 diabetes trials) alongside publicly reported research protocols, for educational use only.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Quick answers about guide scope, access, and educational use context.
What is cagrilintide?
Cagrilintide (AM833) is a long-acting synthetic amylin analog studied as an amylin-receptor agonist for weight management and metabolic disease, most notably in combination with semaglutide (CagriSema). It is investigational and provided for research use only.
How is cagrilintide dosed in studies?
Trials reported once-weekly subcutaneous dosing, typically starting near 0.25 mg and escalating in ~4-week steps, with 2.4 mg as the most-studied maintenance example and up to 4.5 mg examined in dose-finding. These are reported examples, not a recommendation.
What is its half-life?
Reported at roughly 7-8 days (about 159-195 hours), which supports the once-weekly schedule used in research.
How does it differ from semaglutide?
Semaglutide is a GLP-1 receptor agonist, while cagrilintide activates amylin receptors (calcitonin receptor with RAMP proteins). Because the pathways differ, the two are studied together for additive appetite effects.
Is cagrilintide approved or WADA-banned?
It is not FDA-approved as a standalone; the CagriSema combination was under FDA review in 2026. Cagrilintide is not specifically named on the WADA Prohibited List, but athletes should verify current WADA status independently, as weight-loss and metabolic agents can carry sport-specific restrictions.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
